vimarsana.com

Page 10 - ஈராஸ்மஸ் பல்கலைக்கழகம் மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

How COVID Is Changing the Cold and Flu Season

Scientific American How COVID Is Changing the Cold and Flu Season Measures meant to tame the coronavirus pandemic are quashing influenza and most other respiratory diseases, which could have wide-ranging implications Print Despite signs of reduced influenza transmission, people in the United States are being encouraged to get the vaccine. Credit: Jeffrey Greenberg Getty Images Advertisement By mid-December, the Northern Hemisphere is usually well into the start of its annual cold and flu season but so far this year, even as the COVID-19 pandemic surges in dozens of countries, the levels of many common seasonal infections remain extremely low. The pandemic caused by the SARS-CoV-2 coronavirus has infected at least 67 million people and killed 1.5 million worldwide. The patchwork of responses intended to fight the pandemic from temporary lockdowns to mask wearing, social distancing, enhanced personal hygiene and reduced travel has had a huge impact on other common respiratory

Aerosonic Corporation (AMEX:AIM) - AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer

Investegate |AIM ImmunoTech Inc Announcements | AIM ImmunoTech Inc : AIM ImmunoTech s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer

AIM ImmunoTech Inc. AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer OCALA, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the company’s Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer. Medications that have been designated as Orphan products by the European Medicines Agency (EMA), once commercially approved in the European Union (EU), receive benefits including up to ten years of protection from market competition from similar medicines with similar active component and indication for use that are not shown to be cli

AIM ImmunoTech Inc developing immuno-therapeutics to treat multiple types of cancers and fighting coronavirus too

AIM ImmunoTech Inc developing immuno-therapeutics to treat multiple types of cancers and fighting coronavirus too
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.